The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. If recommended, compounding pharmacies could legally prepare these compounds for the first time.

Industry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide May 1, 2026 · Regulatory On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the …